Product Information
DIFLUNISAL 500 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.0645 per EA under NDC 00093922205. Its NADAC has been published 206 times since Oct 26, 2022.
FDA first approved this application on Jul 31, 1992. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093922205
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DIFLUNISALApproval Type
Generic (ANDA)
FDA Application
ANDA073673FDA Approved
7/31/1992
TE Code
AB
On Market Since
6/30/2021
Pharmacological Classes
Price Statistics
The NADAC for DIFLUNISAL 500 MG TABLET has been published 206 times since Oct 26, 2022, and over the history we have for it it has declined 6.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0645 per EA |
|---|---|
| All-time high | $1.2455 (Apr 10, 2024) |
| All-time low | $0.8327 (Dec 21, 2022) |
| 52-week high | $1.1995 |
| 52-week low | $1.0380 |
| Median price | $1.0380 |
| Average price | $1.0466 |
| Largest weekly change | -29.8% (Dec 21, 2022) |
| Weeks tracked | 206 |
| Tracking since | Oct 26, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Diflunisal market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DIFLUNISAL 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DIFLUNISAL 500 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $1.0645 per EA (NDC 00093922205), effective Sep 30, 2026.
How has the price of DIFLUNISAL 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for DIFLUNISAL 500 MG TABLET has declined 6.5%. It has been tracked across 206 weekly CMS publications since Oct 26, 2022.
What are the highest and lowest recorded NADAC prices for DIFLUNISAL 500 MG TABLET?
Since Oct 26, 2022, the NADAC for DIFLUNISAL 500 MG TABLET has ranged from a low of $0.8327 (Dec 21, 2022) to a high of $1.2455 (Apr 10, 2024), with a median of $1.0380 per EA.
Are there cheaper alternatives to DIFLUNISAL 500 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DIFLUNISAL 500 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DIFLUNISAL 500 MG TABLET?
DIFLUNISAL 500 MG TABLET (NDC 00093922205) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.